By physician referral or invitation only

Long-Term Safety and Tolerability of Cendakimab for Patients With EoE

Researchers are studying the long-term safety and tolerability of cendakimab for patients with eosinophilic esophagitis ("EoE"). The researchers hope to provide evidence to prove that cendakimab is a safe and effective medication for long-term EoE treatment.

Age & Gender

12 years ~ 75 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

Evan Dellon
Medicine-Gastroenterology

Study Type

Clinical or Medical
Observational

Study Topics

Allergy
Chronic Conditions
Stomach, Digestion and Gut Health
Ear, Nose, and Throat
Eating, Nutrition, and Metabolism
Immune System/Infections
Rare Diseases

IRB Number

22-0429

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.